Year All 2026 2025 2024 2023 2022 November 3, 2026 Ceribell Reports Third Quarter 2026 Financial Results November 2, 2026 Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution October 28, 2026 Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum October 20, 2026 Ceribell to Report Third Quarter 2026 Financial Results on November 3, 2026 September 30, 2026 Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis August 10, 2026 Ceribell Reports Second Quarter 2026 Financial Results August 10, 2026 Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review August 3, 2026 Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System July 29, 2026 Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe July 28, 2026 Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference
November 2, 2026 Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution
October 28, 2026 Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
September 30, 2026 Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis
August 10, 2026 Ceribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG Review
August 3, 2026 Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System
July 29, 2026 Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe
